Keywords
Influenza life cycle
Antiviral
Licensed drugs
Amantadine
Rimantadine
Oseltamivir
Zanamivir
Peramivir Laninamivir
Ribavirin
Arbidol
Abstract
Influenza is a contagious respiratory acute viral disease charac- terized by a short incubation period, high fever and respiratory and systemic symptoms. The burden of influenza is very heavy. Indeed, the World Health Organization (WHO) estimates that annual epidemics affect 5-15% of the world?s population, causing up to 4-5 million severe cases and from 250,000 to 500,000 deaths. In order to design anti-influenza molecules and compounds, it is important to understand the complex replication cycle of the influenza virus. Replication is achieved through various stages. First, the virus must engage the sialic acid receptors present on the free surface of the cells of the respiratory tract. The virus can then enter the cells by different routes (clathrin-mediated endocytosis or CME, caveolae-dependent endocytosis or CDE, clathrin-caveolae-independent endocytosis, or macropinocyto- sis). CME is the most usual pathway; the virus is internalized into an endosomal compartment, from which it must emerge in order to release its nucleic acid into the cytosol. The ribonucleo- protein must then reach the nucleus in order to begin the pro- cess of translation of its genes and to transcribe and replicate its nucleic acid. Subsequently, the RNA segments, surrounded by the nucleoproteins, must migrate to the cell membrane in order to enable viral assembly. Finally, the virus must be freed to invade other cells of the respiratory tract. All this is achieved through a synchronized action of molecules that perform multi- ple enzymatic and catalytic reactions, currently known only in part, and for which many inhibitory or competitive molecules have been studied. Some of these studies have led to the devel- opment of drugs that have been approved, such as Amantadine, Rimantadine, Oseltamivir, Zanamivir, Peramivir, Laninamivir, Ribavirin and Arbidol. This review focuses on the influenza life- cycle and on the currently available drugs, while potential anti- viral compounds for the prevention and treatment of influenza are considered in the subsequent review.References
Schutten M, van Baalen C, Zoeteweij P, et al. The influenza virus: disease, diagnostics, and treatment. MLO Med Lab Obs 2013;45:38-40.
CDC. Seasonal Influenza: Flu Basics. Document available at: http://www.cdc.gov/flu/about/disease/index.htm. Accessed on 01 August 2014.
Toovey S. Influenza-associated central nervous system dysfunc- tion: a literature review. Travel Med Infect Dis 2008;6:114-24.
Davis LE, Koster F, Cawthon A. Neurologic aspects of influ- enza viruses. Handb Clin Neurol 2014;123:619-45.
Short KR, Habets MN, Hermans PW, et al. Interactions be- tween streptococcus pneumoniae and influenza virus: a mutu- ally beneficial relationship? Future Microbiol 2012;7:609-24.
McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol 2014;12:252-62.
Cauldwell AV, Long JS, Moncorgé O, et al. Viral determinants of influenza a virus host range. J Gen Virol 2014;95:1193-210.
WHO. Influenza (seasonal). Fact sheet N°211 March 2014. Available at: http://www.who.int/mediacentre/factsheets/fs211/ en/. Accessed on 1st August 2014.
ECDC. Seasonal Influenza. Document available at: http://www. ecdc.europa.eu/en/healthtopics/seasonal_influenza/Pages/in- dex.aspx. Accessed on 10th June 2014.
FLU.gov. Seasonal Flu. Document available at: http://www.flu. gov/about_the_flu/seasonal/. Accessed on 1st August 2014.
Bouvier NM, Palese P. The biology of influenza viruses. Vac- cine 2008;26(Suppl 4):D49-53.
Chen J, Deng YM. Influenza virus antigenic variation, hostantibody production and new approach to control epidemics. Virol J 2009;6:30.
Labella AM, Merel SE. Influenza. Med Clin North Am 2013;97:621-45.
Taubenberger JK. The origin and virulence of the 1918 “span- ish” influenza virus. Proc Am Philos Soc 2006;150:86-112.
Patterson KD, Pyle GF. The geography and mortality of the 1918 influenza pandemic. Bull Hist Med 1991;65:4-21.
Stanford University. The medical and scientific concep- tions of influenza. Document available at: http://www.stan- ford.edu/group/virus/uda/fluscimed.html. Accessed on 14th June 2014.
Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of 1-adamantanamine (amantadine). Science 1964;144:862-3.
Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982;307:580-4.
Center for disease Control and Prevention (CDC). Advisory Committee on Immunization Practice (ACIP). Prevention and control of influenza. MMWR Recommendations and Reports 2000;49:1-38.
Noda T, Sagara H, Yen A, et al. Architecture of ribonucleo- protein complexes in influenza a virus particles. Nature 2006;439:490-2.
Noda T. Native morphology of influenza virions. Front Micro- biol 2012;2:269.
Elleman CJ, Barclay WS. The M1 matrix protein controls the filamentous phenotype of influenza A virus. Virology 2004;321:144-53.
Roberts PC, Lamb RA, Compans RW. The M1 and M2 proteins of influenza a virus are important determinants in filamentous particle formation. Virology 1998;240:127-37.
Rossman JS, Jing X, Leser GP, et al. Influenza virus m2 ion channel protein is necessary for filamentous virion formation. J Virol 2010;84:5078-88.
Bialas KM, Bussey KA, Stone RL, et al. Specific nucleo- protein residues affect influenza virus morphology. J Virol 2014;88:2227-34.
Roberts PC, Compans RW. Host cell dependence of viral mor- phology. Proc Natl Acad Sci U S A 1998;95:5746-51.
Samji T. Influenza A: understanding the viral life cycle. Yale J Biol Med 2009;82:153-9.
Cross TA. Flu BM2 structure and function. Nat Struct Mol Biol 2009;16:1207-9.
Pleschka S, Klenk HD, Herrler G. The catalytic triad of the in- fluenza C virus glycoprotein HEF esterase: characterization by site-directed mutagenesis and functional analysis. J Gen Virol 1995;76:2529-37.
Kollerova E, Betáková T. Influenza viruses and their ion chan- nels. Acta Virol 2006;50:7-16.
Fischer WB, Sansom MS. Viral ion channels: structure and function. Biochim Biophys Acta 2002;1561:27-45.
Lamb RA, Choppin PW. The gene structure and replication of influenza virus. Annu Rev Biochem 1983;52:467-506.
Košík I, Hollý J, Russ G. PB1-F2 expedition from the whole protein through the domain to aa residue function. Acta Virol 2013;57:138-48.
Krumbholz A, Philipps A, Oehring H, et al. Current knowledge on PB1-F2 of influenza A viruses. Med Microbiol Immunol 2011;200:69-75.
Košík I, Krejnusová I, Práznovská M, et al. The multifaceted ef- fect of PB1-F2 specific antibodies on influenza a virus infection. Virology 2013;447:1-8.
Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fundamental vi- rology. Philadelphia: Williams & Williams 2001, pp. 725-69.
Skehel JJ. Polypeptide synthesis in influenza virus-infected cells. Virology 1972;49:23-36.
Skehel JJ. Early polypeptide synthesis in influenza virus-infect- ed cells. Virology 1973;56:394-9.
Hayden FG, Aoki FY. Amantadine, rimatadine, and related agents. In: Barriere SL, ed. Antimicrobial therapy and vaccines. Baltimore: Williams & Williams 1999 pp. 1344-65.
Wise HM, Barbezange C, Jagger BW, et al. Overlapping sig- nals for translational regulation and packaging of influenza a virus segment 2. Nucleic Acids Res 2011;39:7775-90.
Wise HM, Hutchinson EC, Jagger BW, et al. Identification of a novel splice variant form of the influenza a virus M2 ion chan- nel with an antigenically distinct ectodomain. PLoS Pathog 2012;8:e1002998.
Yewdell JW, Ince WL. Virology. Frameshifting to PA-X influ- enza. Science 2012;337:164-5.
Muramoto Y, Noda T, Kawakami E, et al. Identification of nov- el influenza a virus proteins translated from PA mRNA. J Virol 2013;87:2455-62.
Vasin AV, Temkina OA, Egorov VV, et al. Molecular mechanisms enhancing the proteome of influenza A virus- es: an overview of recently discovered proteins. Virus Res 2014;185:53-63.
Sabath N, Morris JS, Graur D. Is there a twelfth protein-coding gene in the genome of influenza A? A selection-based approach to the detection of overlapping genes in closely related sequenc- es. J Mol Evol 2011;73:305-15.
Kummer S, Flöttmann M, Schwanhäusser B, et al. Alteration of protein levels during influenza virus H1N1 infection in host cells: a proteomic survey of host and virus reveals differential dynamics. PLoS One 2014;9:e94257.
Matsuoka Y, Matsumae H, Katoh M, et al. A comprehensive map of the influenza a virus replication cycle. BMC Syst Biol 2013;7:97.
Edinger TO, Pohl MO, Stertz S. Entry of influenza A virus: host factors and antiviral targets. J Gen Virol 2014;95:263-77.
Mao H, Tu W, Qin G, et al. Influenza virus directly infects human natural killer cells and induces cell apoptosis. J Virol 2009;83:9215-22.
Sun X, Whittaker GR. Entry of influenza virus. Adv Exp Med Biol 2013;790:72-82.
Roberson EC, Tully JE, Guala AS, et al. Influenza induces en- doplasmic reticulum stress, caspase-12-dependent apoptosis, and c-Jun N-terminal kinase-mediated transforming growth factor-β release in lung epithelial cells. Am J Respir Cell Mol Biol 2012;46:573-81.
Barbier D, Garcia-Verdugo I, Pothlichet J, et al. Influenza A in- duces the major secreted airway mucin MUC5AC in a protease- EGFR-extracellular regulated kinase-Sp1-dependent pathway. Am J Respir Cell Mol Biol 2012;47:149-57.
Ehrhardt C, Marjuki H, Wolff T, et al. Bivalent role of the phos- phatidylinositol-3-kinase (PI3K) during influenza virus infec- tion and host cell defence. Cell Microbiol 2006;8:1336-48.
Air GM. Influenza virus-glycan interactions. Curr Opin Virol 2014;7:128-33.
Shinya K, Ebina M, Yamada S, et al. Avian flu: influenza virus receptors in the human airway. Nature 2006;440:435-6.
Russell RJ, Kerry PS, Stevens DJ, et al. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fu- sion. Proc Natl Acad Sci U S A 2008;105:17736-41.
Sączyńska V. Influenza virus hemagglutinin as a vaccine anti- gen produced in bacteria. Acta Biochim Pol 2014;61:561-72.
Smrt ST, Draney AW, Lorieau JL. The influenza hemagglutinin fusion domain is an amphipathic helical-hairpin that functions by inducing membrane curvature. J Biol Chem 2014 Nov 14. pii: jbc.M114.611657.
Burke DF, Smith DJ. A Recommended numbering scheme for influenza A HA subtypes. PLoS One 2014;9:e112302.
Tong S, Li Y, Rivailler P, et al. A distinct lineage of influenza a virus from bats. Proc Natl Acad Sci U S A 2012;109:4269-74.
Tong S, Zhu X, Li Y, et al. New world bats harbor diverse in- fluenza A viruses. PLoS Pathog 2013;9:e1003657.
Vanderlinden E, Naesens L. Emerging antiviral strategies to in- terfere with influenza virus entry. Med Res Rev 2014;34:301-39.
Stray SJ, Cummings RD, Air GM. Influenza virus infection of desialylated cells. Glycobiology 2000;10:649-58.
Lakadamyali M, Rust MJ, Zhuang X. Endocytosis of influenza viruses. Microbes Infect 2004;6:929-36.
de Vries E, Tscherne DM, Wienholts MJ, et al. Dissection of the influenza a virus endocytic routes reveals macropinocytosis as an alternative entry pathway. PLoS Pathog 2011;7:e1001329.
Rossman JS, Leser GP, Lamb RA. Filamentous influenza virus enters cells via macropinocytosis. J Virol 2012;86:10950-60.
Zhang Y, Whittaker GR. Influenza entry pathways in polarized MDCK cells. Biochem Biophys Res Commun 2014;450:234-9.
Nunes-Correia I, Eulálio A, Nir S, et al. Caveolae as an addi- tional route for influenza virus endocytosis in MDCK cells. Cell Mol Biol Lett 2004;9:47-60.
Sieczkarski SB, Whittaker GR. Influenza virus can enter and infect cells in the absence of clathrin-mediated endocytosis. J Virol 2002;76:10455-64.
Young A. Structural insights into the clathrin coat. Semin Cell Dev Biol 2007;18:448-58.
Wilbur JD, Hwang PK, Brodsky FM. New faces of the familiar clathrin lattice. Traffic 2005;6:346-50.
Heilker R, Manning-Krieg U, Zuber JF, et al. In vitro binding of clathrin adaptors to sorting signals correlates with endocytosis and basolateral sorting. EMBO J 1996;15:2893-9.
Fire E, Brown CM, Roth MG, et al. Partitioning of proteins into plasma membrane microdomains. Clustering of mutant influen- za virus hemagglutinins into coated pits depends on the strength of the internalization signal. J Biol Chem 1997;272:29538-45.
Chen C, Zhuang X. Epsin 1 is a cargo-specific adaptor for the clathrin-mediated endocytosis of the influenza virus. Proc Natl Acad Sci U S A 2008;105:11790-5.
Fujioka Y, Tsuda M, Hattori T, et al. The Ras-PI3K signaling pathway is involved in clathrin-independent endocytosis and the internalization of influenza viruses. PLoS One 2011;6:e16324.
Ayllon J, García-Sastre A, Hale BG. Influenza a viruses and PI3K: are there time, place and manner restrictions? Virulence 2012;3:411-4.
Marchant DJ, Bilawchuk L, Nish G, Hegele RG. Virus-induced signaling influences endosome trafficking, virus entry, and rep- lication. Methods Enzymol 2014;534:65-76.
Pascua PN, Lee JH, Song MS, et al. Role of the p21-activated kinases (PAKs) in influenza a virus replication. Biochem Bio- phys Res Commun 2011;414:569-74.
Nanbo A, Imai M, Watanabe S, et al. Ebolavirus is internal- ized into host cells via macropinocytosis in a viral glycoprotein- dependent manner. PLoS Pathog 2010;6:e1001121.
Saeed MF, Kolokoltsov AA, Albrecht T, et al. Cellular en- try of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog 2010;6:e1001110.
Iwasaki M, Ngo N, de la Torre JC. Sodium hydrogen exchang- ers contribute to arenavirus cell entry. J Virol 2014;88:643-54.
Amstutz B, Gastaldelli M, Kälin S, et al. Subversion of CtBP1- controlled macropinocytosis by human adenovirus serotype 3. EMBO J 2008;27:956-69.
Kälin S, Amstutz B, Gastaldelli M, et al. Macropinocytotic up- take and infection of human epithelial cells with species B2 ad- enovirus type 35. J Virol 2010;84:5336-50.
Schelhaas M, Shah B, Holzer M, et al. Entry of human papil- lomavirus type 16 by actin-dependent, clathrin- and lipid raft- independent endocytosis. PLoS Pathog 2012;8:e1002657.
Carter GC, Bernstone L, Baskaran D, et al. HIV-1 infects mac- rophages by exploiting an endocytic route dependent on dy- namin, Rac1 and Pak1. Virology. 2011 Jan 20;409(2):234-50.
Nagasawa S, Ogura K, Tsutsuki H, et al. Uptake of shiga- toxigenic escherichia coli subAB by HeLa cells requires an actin – and lipid raft-dependent pathway. Cell Microbiol 2014;16:1582-601.
Barrias ES, Reignault LC, De Souza W, et al. Trypanosoma cruzi uses macropinocytosis as an additional entry pathway into mammalian host cell. Microbes Infect 2012;14:1340-51.
Mercer J, Helenius A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 2008;320:531-5.
Sánchez EG, Quintas A, Pérez-Núñez D, et al. African swine fever virus uses macropinocytosis to enter host cells. PLoS Pat- hog 2012;8:e1002754.
Krzyzaniak MA, Zumstein MT, Gerez JA, et al. Host cell entry of respiratory syncytial virus involves macropinocytosis fol- lowed by proteolytic activation of the F protein. PLoS Pathog 2013;9:e1003309.
Matsuda M, Suzuki R, Kataoka C, et al. Alternative endocytosis pathway for productive entry of hepatitis C virus. J Gen Virol 2014;95:2658-67.
De Conto F, Covan S, Arcangeletti MC, et al. Differential in- fectious entry of human influenza A/NWS/33 virus (H1N1) in mammalian kidney cells. Virus Res 2011;155:221-30.
Liu SL, Wu QM, Zhang LJ, et al. Three-dimensional tracking of rab5- and rab7 – associated infection process of influenza virus. Small 2014 Jun 27. doi: 10.1002/smll.201400944.
Huotari J, Helenius A. Endosome maturation. EMBO J 2011;30:3481-500.
Sieczkarski SB, Whittaker GR. Differential requirements of Rab5 and Rab7 for endocytosis of influenza and other envel- oped viruses. Traffic 2003;4:333-43.
Costello DA, Whittaker GR, Daniel S. Variation of pH sensitiv- ity, acid stability, and fusogenicity of three influenza H3 sub- types. J Virol 2014 Oct 15. pii: JVI.01927-14.
Khor R, McElroy LJ, Whittaker GR. The ubiquitin-vacuolar protein sorting system is selectively required during entry of influenza virus into host cells. Traffic 2003;4:857-68.
Zhou Z, Xue Q, Wan Y, et al. Lysosome-associated membrane glycoprotein 3 is involved in influenza a virus replication in hu- man lung epithelial (A549) cells. Virol J 2011;8:384.
Davenport EE, Antrobus RD, Lillie PJ, et al. Transcriptomic profiling facilitates classification of response to influenza chal- lenge. J Mol Med (Berl) 2014 Oct 28.
Hubner M, Peter M. Cullin-3 and the endocytic system: new functions of ubiquitination for endosome maturation. Cell Lo- gist 2012;2:166-168.
Huotari J, Meyer-Schaller N, Hubner M, et al. Cullin-3 regu- lates late endosome maturation. Proc Natl Acad Sci U S A 2012;109:823-8.
Li S, Sieben C, Ludwig K, et al. pH-Controlled two-step un- coating of influenza virus. Biophys J 2014;106:1447-56.
Pinto LH, Lamb RA. The M2 Proton Channels of Influenza A and B Viruses. J Biol Chem 2006;281:8997.
Martyna A, Rossman. Alterations of membrane curvature during influenza virus budding. J Biochem Soc Trans 2014;42:1425-8.
Fuhrmans M, Marrink SJ. Molecular view of the role of fu- sion peptides in promoting positive membrane curvature. J Am Chem Soc 2012;134:1543-52.
Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000;69:531-69.
Bentz J, Mittal A. Architecture of the influenza hemagglutinin membrane fusion site. Biochim Biophys Acta 2003;1614:24-35.
Kido H, Okumura Y, Takahashi E, et al. Role of host cel- lular proteases in the pathogenesis of influenza and influ- enza-induced multiple organ failure. Biochim Biophys Acta 2012;1824:186-94.
Zhirnov PO, Matrosovich TY, Matrosovich MN, et al. Apro- tinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. Antivir Chem Chemoth 2011;21:169-74.
Seki M, Kohno S, Newstead MW, et al. Critical role of IL-1 receptor-associated kinase-M in regulating chemokine-depend- ent deleterious inflammation in murine influenza pneumonia. J Immunol 2010;184:1410-8.
Banerjee I, Miyake Y, Nobs SP, et al. Influenza a virus uses the aggresome processing machinery for host cell entry. Science 2014;346:473-7.
Sakaguchi T, Leser GP, Lamb RA. The ion channel activity of the influenza virus M2 protein affects transport through the Golgi apparatus. J Cell Biol 1996;133:733-47.
Ciampor F, Cmarko D, Cmarková J, et al. Influenza virus M2 protein and haemagglutinin conformation changes during in- tracellular transport. Acta Virol 1995;39: 171-81.
Zhirnov OP, Klenk HD. Influenza a virus proteins NS1 and he- magglutinin along with M2 are involved in stimulation of au- tophagy in infected cells. J Virol 2013;87:13107-14.
Gu RX, Liu LA, Wei DQ. Structural and energetic analysis of drug inhibition of the influenza A M2 proton channel. Trends Pharmacol Sci 2013;34:571-80.
Tawaratsumida K, Phan V, Hrincius ER, et al. Quantita- tive proteomic analysis of the influenza a virus nonstructural proteins NS1 and NS2 during natural cell infection identifies PACT as an NS1 target protein and antiviral host factor. J Virol 2014;88:9038-48.
Li S, Min JY, Krug RM, et al. Binding of the influenza a virus NS1 protein to PKR mediates the inhibition of its ac- tivation by either PACT or double-stranded RNA. Virology 2006;349:13-21.
Khaperskyy DA, Emara MM, Johnston BP, et al. Influenza a virus host shutoff disables antiviral stress-induced translation arrest. PLoS Pathog 2014;10:e1004217.
Ludwig S, Wolff T. Influenza a virus TRIMs the type I inter- feron response. Cell Host Microbe 2009;5:420-1.
Gack MU, Albrecht RA, Urano T, et al. Influenza a virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009;5:439-49.
Ngamurulert S, Limjindaporn T, Auewaraku P. Identifica- tion of cellular partners of Influenza a virus (H5N1) non- structural protein NS1 by yeast two-hybrid system. Acta Virol 2009;53:153-9.
Kolocouris A, Spearpoint P, Martin SR, et al. Comparisons of the influenza virus A M2 channel binding affinities, anti- influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues. Bioorg Med Chem Lett 2008;18:6156-60.
Kozakov D, Chuang GY, Beglov D, et al. Where does aman- tadine bind to the influenza virus M2 proton channel? Trends Biochem Sci 2010;35:471-5.
Laohpongspaisan C, Rungrotmongkol T, Loisruangsin A, et al. How amantadine and rimantadine inhibit proton transport in the M2 protein channel. J Mol Graph Model 2008;27:342-8.
Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008;451:591-5.
Liang R, Li H, Swanson JM, et al. Multiscale simulation re- veals a multifaceted mechanism of proton permeation through the influenza A M2 proton channel. Proc Natl Acad Sci U S A 2014;111:9396-401.
Babcock HP, Chen C, Zhuang X. Using single-particle track- ing to study nuclear trafficking of viral genes. Biophys J 2004;87:2749-58.
Influenza life cycle pathway map. FluMap interactive view. Flu- Map: a comprehensive influenza life cycle map. Available at: http://www.influenza-x.org/flumap/Pathway.html. Accessed on 1st August 2014.
Pumroy RA, Nardozzi JD, Hart DJ, et al. Nucleoporin Nup50 stabilizes closed conformation of armadillo repeat 10 in impor- tin α5. J Biol Chem 2012;287:2022-31.
Tafforeau L, Chantier T, Pradezynski F, et al. Generation and comprehensive analysis of an influenza virus polymerase cel- lular interaction network. J Virol 2011;85:13010-8.
Munier S, Rolland T, Diot C, et al. Exploration of binary virus- host interactions using an infectious protein complementation assay. Mol Cell Proteomics 2013;12:2845-55.
Martin K, Helenius A. Transport of incoming influenza virus nucleocapsids into the nucleus. J Virol 1991;65:232-44.
Satterly N, Tsai PL, van Deursen J, et al. Influenza virus tar- gets the mRNA export machinery and the nuclear pore complex. Proc Natl Acad Sci U S A 2007;104:1853-8.
Read EK, Digard P. Individual influenza a virus mRNAs show differential dependence on cellular NXF1/TAP for their nuclear export. J Gen Virol 2010;91:1290-301.
Chen J, Huang S, Chen Z. Human cellular protein nucleoporin hNup98 interacts with influenza a virus NS2/nuclear export protein and overexpression of its GLFG repeat domain can in- hibit virus propagation. J Gen Virol 2010;91:2474-84.
Beck M, Glavy JS. Toward understanding the structure of the vertebrate nuclear pore complex. Nucleus 2014;5:119-23.
Shi F, Xie Y, Shi L, et al. Viral RNA polymerase: a promising anti- viral target for influenza A virus. Curr Med Chem 2013;20:3923-34.
Hudjetz B, Gabriel G. Human-like PB2 627K influenza virus polymerase activity is regulated by importin-alpha1 and -al- pha7. PLoS Pathog 2012;8:e1002488.
Chou YY, Heaton NS, Gao Q, et al. Colocalization of differ- ent influenza viral RNA segments in the cytoplasm before viral budding as shown by single-molecule sensitivity FISH analysis. PLoS Pathog 2013;9:e1003358.
Resa-Infante P, Gabriel G. The nuclear import machinery is a determinant of influenza virus host adaptation. ResaBioessays 2013;35:23-7.
Gabriel G, Herwig A, Klenk HD. Interaction of polymerase subunit PB2 and NP with importin alpha1 is a determinant of host range of influenza a virus. PLoS Pathog 2008;4:e11.
Manzoor R, Kuroda K, Yoshida R, et al. Heat shock protein 70 modulates influenza a virus polymerase activity. J Biol Chem 2014;289:7599-614.
Zhang C, Yang Y, Zhou X, et al. The NS1 protein of influenza a virus interacts with heat shock protein Hsp90 in human alveo- lar basal epithelial cells: implication for virus-induced apopto- sis. Virol J 2011;8:181.
Naito T, Momose F, Kawaguchi A, et al. Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA poly- merase subunits. J Virol 2007;81:1339-49.
Cao M, Wei C, Zhao L, et al. DnaJA1/Hsp40 is co-opted by influenza a virus to enhance its viral RNA polymerase activity. J Virol 2014 Sep 24. pii: JVI.02475-14.
Pérez-González A, Rodriguez A, Huarte M, et al. hCLE/CGI- 99, a human protein that interacts with the influenza virus polymerase, is a mRNA transcription modulator. J Mol Biol 2006;362:887-900.
Kawaguchi A, Nagata K. De novo replication of the influenza virus RNA genome is regulated by DNA replicative helicase, MCM. EMBO J 2007;26:4566-75.
Bier K, York A, Fodor E. Cellular cap-binding proteins associ- ate with influenza virus mRNAs. J Gen Virol 2011;92:1627-34.
Reich S, Guilligay D, Pflug A, et al. Structural insight into cap- snatching and RNA synthesis by influenza polymerase. Nature 2014 Nov 19. doi: 10.1038/nature14009.
Hatakeyama D, Shoji M, Yamayoshi S, et al. A novel functional site in the PB2 subunit of influenza a virus essential for acetyl- CoA interaction, RNA polymerase activity, and viral replica- tion. J Biol Chem 2014;289:24980-94.
Hutchinson EC, Fodor E. Transport of the Influenza Virus Ge- nome from Nucleus to Nucleus. Viruses 2013;5:2424-46.
York A, Fodor E. Biogenesis, assembly, and export of viral messenger ribonucleoproteins in the influenza a virus infected cell. RNA Biol 2013;10:1274-82.
Fodor E. The RNA polymerase of influenza A virus: mech- anisms of viral transcription and replication. Acta Virol 2013;57:113-22.
Momose F, Basler CF, O’Neill RE, et al. Cellular splicing fac- tor RAF-2p48/NPI-5/BAT1/UAP56 interacts with the influenza virus nucleoprotein and enhances viral RNA synthesis. J Virol 2001;75:1899-908.
Naito T, Momose F, Kawaguchi A, et al. Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA poly- merase subunits. J Virol 2007;81:1339-49.
Vreede FT, Brownlee GG. Influenza virion-derived viral ribo- nucleoproteins synthesize both mRNA and cRNA in vitro. J Vi- rol 2007;81:2196-204.
Perez JT, Varble A, Sachidanandam R, et al. Influenza a virus- generated small RNAs regulate the switch from transcription to replication. Proc Natl Acad Sci U S A 2010;107:11525-30.
Hutchinson EC, Fodor E. Nuclear import of the influenza a vi- rus transcriptional machinery. Vaccine 2012;30:7353-8.
Loucaides EM, von Kirchbach JC, Foeglein A, et al. Nuclear dynamics of influenza a virus ribonucleoproteins revealed by live-cell imaging studies. Virology 2009;394:154-63.
Resa-Infante P, Jorba N, Zamarreno N, et al. The host-depend- ent interaction of alpha-importins with influenza PB2 polymer- ase subunit is required for virus RNA replication. PLoS One 2008;3:e3904.
Portela A, Digard P. The influenza virus nucleoprotein: a mul- tifunctional RNA-binding protein pivotal to virus replication. J Gen Virol 2002;83:723-34.
Amorim MJ, Read EK, Dalton RM, et al. Nuclear export of in- fluenza a virus mRNAs requires ongoing RNA polymerase II activity. Traffic 2007;8:1-11.
Moeller A, Kirchdoerfer RN, Potter CS, et al. Organiza- tion of the influenza virus replication machinery. Science 2012;338:1631-4.
Zheng W, Tao YJ. Structure and assembly of the influenza a vi- rus ribonucleoprotein complex. FEBS Lett 2013;587:1206-14.
Su CY, Cheng TJ, Lin MI, et al. High-throughput identification of compounds targeting in2l6enza RNA-dependent RNA poly- merase activity. Proc Natl Acad Sci U S A 2010;107:19151-6.
Landeras-Bueno S, Jorba N, Pérez-Cidoncha M, et al. The splic- ing factor proline-glutamine rich (SFPQ/PSF) is involved in in- fluenza virus transcription. PLoS Pathog 2011;7:e1002397.
Tsai PL, Chiou NT, Kuss S, et al. Cellular RNA binding pro- teins NS1-BP and hnRNP K regulate influenza a virus RNA splicing. PLoS Pathog 2013;9:e1003460.
Dubois J, Terrier O, Rosa-Calatrava M. Influenza viruses and mRNA splicing: doing more with less. MBio 2014;5:e00070-14.
Perwitasari O, Johnson S, Yan X, et al. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo. J Virol 2014;88:10228-43.
Simon JP, Ivanov IE, Shopsin B, et al. The in vitro genera- tion of post-Golgi vesicles carrying viral envelope glycopro- teins requires an ARF-like GTP-binding protein and a protein kinase C associated with the Golgi apparatus. J Biol Chem 1996;271:16952-61.
Predicala R, Zhou Y. The role of Ran-binding protein 3 during influenza a virus replication. J Gen Virol 2013;94:977-84.
Akarsu H, Burmeister WP, Petosa C, et al. Crystal structure of the M1 protein-binding domain of the influenza a virus nuclear export protein (NEP/NS2). EMBO J 2003;22:4646-55.
Watanabe K, Takizawa N, Noda S, et al. Hsc70 regulates the nuclear export but not the import of influenza viral RNP: a pos- sible target for the development of anti-influenza virus drugs. Drug Discov Ther 2008;2:77-84.
Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol 2007;17:193-201.
Ma K, Roy AM, Whittaker GR. Nuclear export of influenza vi- rus ribonucleoproteins: identification of an export intermediate at the nuclear periphery. Virology 2001;282:215-20.
Santos A, Pal S, Chacón J, et al. SUMOylation affects the inter- feron blocking activity of the influenza A nonstructural protein NS1 without affecting its stability or cellular localization. J Vi- rol 2013;87:5602-20.
Wurzer WJ, Planz O, Ehrhardt C, et al. Caspase 3 activation is essential for efficient influenza virus propagation. EMBO J 2003;22:2717-28.
Marjuki H, Alam MI, Ehrhardt C, et al. Membrane accumula- tion of influenza a virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activa- tion of ERK signaling. J Biol Chem 2006;281:16707-15.
Galli C, Bernasconi R, Soldà T, et al. Malectin participates in a backup glycoprotein quality control pathway in the mammalian ER. PLoS One 2011;6:e16304.
Wang N, Glidden EJ, Murphy SR, et al. The cotranslational maturation program for the type II membrane glycoprotein in- fluenza neuraminidase. J Biol Chem 2008;283:33826-37.
Pearse BR, Gabriel L, Wang N, et al. A cell-based reglucosyla- tion assay demonstrates the role of GT1 in the quality control of a maturing glycoprotein. J Cell Biol 2008;181:309-20.
Hebert DN, Foellmer B, Helenius A. Calnexin and calreticu- lin promote folding, delay oligomerization and suppress deg- radation of influenza hemagglutinin in microsomes. EMBO J 1996;15:2961-8.
Daniels R, Kurowski B, Johnson AE, et al. N-linked glycans direct the cotranslational folding pathway of influenza hemag- glutinin. Mol Cell 2003;11:79-90.
Pleschka S, Wolff T, Ehrhardt C, et al. Influenza virus propaga- tion is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol 2001;3:301-5.
Iwai A, Shiozaki T, Miyazaki T. Relevance of signaling mol- ecules for apoptosis induction on influenza a virus replication. Biochem Biophys Res Commun 2013;441:531-7.
Eisfeld AJ, Kawakami E, Watanabe T, et al. RAB11A is essen- tial for transport of the influenza virus genome to the plasma membrane. J Virol 2011;85:6117-26.
Kawaguchi A, Matsumoto K, Nagata K. YB-1 functions as a porter to lead influenza virus ribonucleoprotein complexes to microtubules. J Virol 2012;86:11086-95.
Momose F, Sekimoto T, Ohkura T, et al. Apical transport of influenza a virus ribonucleoprotein requires Rab11-positive re- cycling endosome. PLoS One 2011;6:e21123.
Jo S, Kawaguchi A, Takizawa N, et al. Involvement of vesicular trafficking system in membrane targeting of the progeny influ- enza virus genome. Microbes Infect 2010;12:1079-84.
Marjuki H, Alam MI, Ehrhardt C, et al. Membrane accumula- tion of influenza a virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activa- tion of ERK signaling. J Biol Chem 2006;281:16707-15.
Hutchinson EC, von Kirchbach JC, Gog JR, et al. Genome packaging ininfluenza a virus. J Gen Virol 2010;91:313-28.
Rossman JS, Lamb RA. Influenza virus assembly and budding. Virology 2011;411:229-36.
Calder LJ, Wasilewski S, Berriman JA, et al. Structural organi- zation of a filamentous influenza a virus. Proc Natl Acad Sci U S A 2010;107:10685-90.
Fournier E, Moules V, Essere B, et al. A supramolecular assem- bly formed by influenza a virus genomic RNA segments. Nucleic Acids Res 2012;40:2197-209.
Rossman JS, Jing X, Leser GP, et al. Influenza virus M2 pro- tein mediates ESCRT-independent membrane scission. Cell 2010;142:902-13.
Eisfeld AJ, Kawakami E, Watanabe T, et al. RAB11A is essen- tial for transport of the influenza virus genome to the plasma membrane. J Virol 2011;85:6117-26.
Eisfeld AJ, Neumann G, Kawaoka Y. Human immunodeficien- cy virus rev-binding protein is essential for influenza a virus replication and promotes genome trafficking in late-stage infec- tion. J Virol 2011;85:9588-98.
Taylor G. Sialidases: structures, biological significance and therapeutic potential. Curr Opin Struct Biol 1996;6:830-7.
Air GM, Laver WG. The neuraminidase of influenza virus. Pro- teins 1989;6:341-56.
Greenway KT, LeGresley EB, Pinto BM. The influence of 150-cavity binders on the dynamics of influenza a neuramini- dases as revealed by molecular dynamics simulations and com- bined clustering. PLoS One 2013;8:e59873.
Watanabe R, Lamb RA. Influenza virus budding does not require a functional AAA+ ATPase, VPS4. Virus Res 2010;153:58-63.
Bruce EA, Medcalf L, Crump CM, et al. Budding of filamentous and non-filamentous influenza a virus occurs via a VPS4 and VPS28-independent pathway. Virology 2009;390:268-78.
Hayden FG, Aoki FY. Amantadine, rimatadine, and related agents. In: Barriere SL, ed. Antimicrobial Therapy and Vac- cines. Baltimore: Williams & Williams 1999, pp. 1344-65.
Wang C, Takeuchi K, Pinto LH, et al. Ion channel activity of in- fluenza a virus M2 protein: characterization of the amantadine block. J Virol 1993;675585-94.
Connolly BS, Lang AE. Pharmacological treatment of Parkin- son disease: a review. JAMA. 2014;311:1670-83.
Stryjer R, Budnik D, Ebert T, et al. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study. Clin Neuropharmacol 2014;37:79-81.
Videnovic A. Treatment of Huntington disease. Curr Treat Op- tions Neurol 2013;15:424-38.
Hosenbocus S, Chahal R. Amantadine: a review of use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychia- try 2013;22:55-60.
Soares BG, Lima MS, Reisser AA, et al. Dopamine ago- nists for cocaine dependence. Cochrane Database Syst Rev 2001;(4):CD003352.
Smith JP, Riley TR, Bingaman S, et al. Amantadine therapy for chronic hepatitis C: a dose escalation study. Am J Gastroen- terol 2004;99:1099-104.
Braham J. Amantadine in the treatment of Creutzfeldt-Jakob disease. Arch Neurol 1984;41:585-6.
Ohlmeier MD, Zhang Y, Bode L, et al. Amantadine reduces mania in borna disease virus-infected non-psychotic bipolar patients. Pharmacopsychiatry 2008;41:202-3.
Colgan R, Michocki R, Greisman L, et al. Antiviral drugs in the immunocompetent host: part I. Treatment of hepatitis, cytomegalovirus, and herpes infections. Am Fam Physician 2003;67:757-62.
Ruigrok RW, Hirst EM, Hay AJ. The specific inhibition of in- fluenza a virus maturation by amantadine: an electron micro- scopic examination. J Gen Virol 1991;72:191-4.
Gu RX, Liu LA, Wei DQ. Structural and energetic analysis of drug inhibition of the influenza A M2 proton channel. Trends Pharmacol Sci 2013;34:571-80.
Ison MG, Hayden FG. Therapeutic options for the management of influenza. Curr Opin Pharmacol 2001;1:482-90.
Allen UD, Aoki FY, Stiver HG. The use of antiviral drugs for influenza: recommended guidelines for practitioners. Can J In- fect Dis Med Microbiol 2006;17:273-84.
Cattoni J, Parekh R. Acute respiratory distress syndrome: a rare presentation of amantadine toxicity. Am J Case Rep 2014;15:1-3.
Alves Galvão MG, Rocha Crispino Santos MA, Alves da Cunha AJ. Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev 2014;(11):CD002745.
Keyser LA, Karl M, Nafziger AN, et al. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 2000;160:1485-8.
Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des 2007;13:3531-42.
Sheu TG, Fry AM, Garten RJ, et al. Dual resistance to ada- mantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. J Infect Dis. 2011;203:13-7.
Ison MG. Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respir Viruses 2013;7(Suppl 1):7-13.
Burnet FM, McCrea JF, Stone JD. Modification of Human Red Cells by Virus Action. I. The Receptor Gradient for Virus Action in Human Red Cells. Br J Exp Pathol 1946;27:228-36.
von Itzstein M, Wu WY, Kok GB, et al. Rational design of po- tent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-23
Tullu MS. Oseltamivir. J Postgrad Med 2009;55:225-30.
Burch J, Paulden M, Conti S, et al. Antiviral drugs for the treat- ment of influenza: a systematic review and economic evalua- tion. Health Technol Assess 2009;13:1-265.
Jackson RJ, Cooper KL, Tappenden P, et al. Oseltamivir, zan- amivir and amantadine in the prevention of influenza: a system- atic review. J Infect 2011;62:14-25.
Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibi- tors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;(4):CD008965.
Beigi RH, Venkataramanan R, Caritis SN. Oseltamivir for in- fluenza in pregnancy. Semin Perinatol 2014 Sep 30. pii: S0146- 0005(14)00103-7.
CDC. Influenza antiviral medications: summary for clinicians (current for the 2013-14 influenza season). Document available at: http://www.cdc.gov/flu/professionals/antivirals/summary- clinicians.htm. accessed on 24th July 2014.
WHO. Global alert and Response (GAR) Antiviral drugs for pan- demic (H1N1) 2009: definitions and use. Document available at: http://www.who.int/csr/disease/swineflu/frequently_asked_ques- tions/antivirals/definitions_use/en/ accessed on 24th July 2014).
Barroso L, Treanor J, Gubareva L, et al. Efficacy and tolerabil- ity of the oral neuraminidase inhibitor peramivir in experimen- tal human influenza: randomized, controlled trials for prophy- laxis and treatment. Antivir Ther 2005;10:901-10.
Birnkrant D, Cox E. The emergency use authorization of per- amivir for treatment of 2009 h1n1 influenza. N Engl J Med 2009;361:2204-7.
Koyama K, Ogura Y, Nakai D, et al. Identification of bioac- tivating enzymes involved in the hydrolysis of laninamivir oc- tanoate, a long-acting neuraminidase inhibitor, in human pul- monary tissue. Drug Metab Dispos 2014;42:1031-8.
Kashiwagi S, Yoshida S, Yamaguchi H, et al. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hy- drate in post-marketing surveillance. Int J Antimicrob Agents 2012;40:381-8.
Katsumi Y, Otabe O, Matsui F, et al. Effect of a single inhala- tion of laninamivir octanoate in children with influenza. Pediat- rics 2012;129:e1431-6.
Yoshiba S, Okabe H, Ishizuka H. Pharmacokinetics of lani- namivir after a single administration of its prodrug, laninami- vir octanoate, a long-acting neuraminidase inhibitor, using an easy-to-use inhaler in healthy volunteers. J Bioequiv Availab 2011;3:001-004.
Streeter DG, Witkowski JT, Khare GP, et al. Mechanism of ac- tion of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Vi- razole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A 1973;70:1174-8.
Crotty S, Cameron C, Andino R. Ribavirin’s antiviral mech- anism of action: lethal mutagenesis? J Mol Med (Berl) 2002;80:86-95.
Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med 2009;361:1713-4.
Uchide N. Ohyama K, Toyoda H. Current and future anti-in- fluenza virus drugs. The Open Antimicrobial Agents Journal 2010;2:34-48.
Deng P, Zhong D, Yu K, et al. Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans. Antimi- crob Agents Chemother 2013;57:1743-55.
Shi L, Xiong H, He J, et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, cox-sackie virus and adenovirus in vitro and in vivo. Arch Virol 2007;152:1447-55.
Di Mola A, Peduto A, La Gatta A, et al. Structure-activity re- lationship study of arbidol derivatives as inhibitors of chikun- gunya virus replication. Bioorg Med Chem 2014 Sep 16. pii: S0968-0896(14)00649-X.
Brooks MJ, Sasadeusz JJ, Tannock GA. Antiviral chemothera- peutic agents against respiratory viruses: where are we now and what’s in the pipeline? Curr Opin Pulm Med 2004;10:197-203.
Blaising J, Lévy PL, Polyak SJ, et al. Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. Antiviral Res 2013;100:215-9.
Wei F, Li JL, Ling JX, et al. Establishment of SYBR green- based qPCR assay for rapid evaluation and quantification for anti-Hantaan virus compounds in vitro and in suckling mice. Virus Genes 2013;46:54-62.
Santesso N, Hsu J, Mustafa R, et al. Antivirals for influenza: a sum- mary of a systematic review and meta-analysis of observational studies. Influenza Other Respir Viruses 2013;7(Suppl 2):76-81.
He G, Qiao J, Dong C, et al. Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Anti- viral Res 2008;77:72-6.